VIR has 36-month beta value of 0.46. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VIR is 88.97M, and currently, short sellers hold a 5.79% ratio of that float. The average trading volume of VIR on May 06, 2024 was 1.04M shares.
VIR) stock’s latest price update
Vir Biotechnology Inc (NASDAQ: VIR)’s stock price has gone rise by 13.18 in comparison to its previous close of 9.18, however, the company has experienced a 26.25% increase in its stock price over the last five trading days. Seeking Alpha reported 2024-05-03 that Vir Biotechnology, Inc. (NASDAQ:VIR ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Sasha Damouni Ellis – Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer – Chief Executive Officer Carrie Huang – Senior Vice President, Clinical Research and Interim Chief Medical Officer Sung Lee – Chief Financial Officer Conference Call Participants Gena Wang – Barclays Paul Choi – Goldman Sachs Alec Stranahan – Bank of America Phil Nadeau – TD Cowen Patrick Trucchio – H.C. Wainwright Rosa Chen – Leerink Partners Joseph Stringer – Needham & Company Eric Joseph – JP Morgan Michaels Ulz – Morgan Stanley Operator Hello.
VIR’s Market Performance
Vir Biotechnology Inc (VIR) has seen a 26.25% rise in stock performance for the week, with a 9.71% gain in the past month and a 19.84% surge in the past quarter. The volatility ratio for the week is 5.12%, and the volatility levels for the past 30 days are at 4.63% for VIR. The simple moving average for the past 20 days is 21.07% for VIR’s stock, with a 1.44% simple moving average for the past 200 days.
Analysts’ Opinion of VIR
Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR by listing it as a “Neutral.” The predicted price for VIR in the upcoming period, according to JP Morgan is $9 based on the research report published on January 29, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see VIR reach a price target of $14, previously predicting the price at $23. The rating they have provided for VIR stocks is “Neutral” according to the report published on September 08th, 2023.
JP Morgan gave a rating of “Overweight” to VIR, setting the target price at $34 in the report published on March 06th of the previous year.
VIR Trading at 5.80% from the 50-Day Moving Average
After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.19% of loss for the given period.
Volatility was left at 4.63%, however, over the last 30 days, the volatility rate increased by 5.12%, as shares surge +11.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.87% upper at present.
During the last 5 trading sessions, VIR rose by +26.25%, which changed the moving average for the period of 200-days by -54.92% in comparison to the 20-day moving average, which settled at $8.63. In addition, Vir Biotechnology Inc saw 3.28% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VIR starting from De Backer Marianne, who sale 72,995 shares at the price of $9.46 back on Apr 03 ’24. After this action, De Backer Marianne now owns 678,457 shares of Vir Biotechnology Inc, valued at $690,365 using the latest closing price.
HANLY ANN M., the EVP & Chief Technology Officer of Vir Biotechnology Inc, sale 2,711 shares at $10.05 during a trade that took place back on Apr 01 ’24, which means that HANLY ANN M. is holding 132,069 shares at $27,251 based on the most recent closing price.
Stock Fundamentals for VIR
Current profitability levels for the company are sitting at:
- -10.63 for the present operating margin
- 0.9 for the gross margin
The net margin for Vir Biotechnology Inc stands at -9.57. The total capital return value is set at -0.35. Equity return is now at value -30.67, with -24.19 for asset returns.
Based on Vir Biotechnology Inc (VIR), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -6.98. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -2506.76.
Currently, EBITDA for the company is -641.55 million with net debt to EBITDA at 0.11. When we switch over and look at the enterprise to sales, we see a ratio of 23.9. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.90.
Conclusion
To put it simply, Vir Biotechnology Inc (VIR) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
